Alexion's Soliris Approved in Japan for Patients with aHUS

Alexion Pharmaceuticals, Inc.

, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved the use of Soliris® (eculizumab) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening ultra-rare disorder. Soliris is already approved in Japan for paroxysmal nocturnal hemoglobinuria (PNH), another severe and ultra-rare disease. Alexion expects that initial patients with aHUS in Japan will commence treatment with Soliris during the fourth quarter of this year. aHUS is a life-threatening and ultra-rare chronic genetic disease that can progressively damage vital organs, leading to stroke, heart attack, kidney failure, and death.1 The morbidities and premature mortality